Chloroform → (6-Bromopyridin-3-yl)[4-(p-tolyloxy)piperidin-1-yl]methanone

HRID 1803965

반응식

HRID 1803965 반응식
[C:1]1([CH3:14])[CH:6]=[CH:5][C:4]([O:7][CH:8]2[CH2:13][CH2:12][NH:11][CH2:10][CH2:9]2)=[CH:3][CH:2]=1.[Br:15][C:16]1[CH:24]=[CH:23][C:19]([C:20](O)=[O:21])=[CH:18][N:17]=1.O.[Cl-].COC1N=C(OC)N=C([N+]2(C)CCOCC2)N=1.C(Cl)(Cl)Cl>CO>[Br:15][C:16]1[N:17]=[CH:18][C:19]([C:20]([N:11]2[CH2:12][CH2:13][CH:8]([O:7][C:4]3[CH:3]=[CH:2][C:1]([CH3:14])=[CH:6][CH:5]=3)[CH2:9][CH2:10]2)=[O:21])=[CH:23][CH:24]=1

참가 물질

6

반응물 4

HCID 6212ChloroformHCID 2389326-Bromonicotinic acidHCID 38374974-(4-Methylphenoxy)piperidineHCID 231494114-(4,6-Dimethoxy[1.3.5]triazin-2-yl)-4-methylmorpholinium chloride hydrate

생성물 1

HCID 58484591(6-Bromopyridin-3-yl)[4-(p-tolyloxy)piperidin-1-yl]methanone수율 99.9%

시약·촉매·용매 1

HCID 887Methanol용매

실험 절차

To a mixture of 4-(p-tolyloxy)piperidine (765 mg), 6-bromonicotinic acid (808 mg) and 4-(4,6-dimethoxy[1.3.5]triazin-2-yl)-4-methylmorpholinium chloride hydrate (DMT-MM) (1.7 g) were added chloroform (5 mL) and methanol (5 mL), and the mixture was stirred at room temperature overnight. After evaporation of the solvent, the residue was purified by column chromatography (chloroform:methanol) to give the title compound (1.5 g).

후처리

  1. customAfter evaporation of the solvent
  2. customthe residue was purified by column chromatography (chloroform:methanol)

출처 및 근거

ORD 기록
ord-31d277f31d42413fbaa18166042e1a7d
출처 데이터셋
uspto-grants-2013_01
특허 번호
US08354401B2

연결된 노트

불러오는 중…